

[401] BLUEWIND MEDICAL RENOVA SYSTEM - NEUROSTIMULATION THERAPY FOR OVER ACTIVE BLADDER

Ofri Vaisman, COO, BlueWind Medical, R&D and Operations, Hezelia, Israel

- **Investment Rational**

The BlueWind RENOVA™ therapy is focused on delivering Over Active Bladder therapy with high risk/benefit ratio based upon proven therapy of Tibial Neurostimulation for these patients as well as great long-term clinical data. The market opportunity is immense due to both the large patient pool with limited current solutions, good awareness for the treatment modality and the easy referral path.

- **Business Strategy**

The company plans to both take market share from current device therapies as well as bridge the gap from pharmaceutical solutions, moving more patients off the watchful waiting position into active therapy. The company is leveraging its significant long-standing partnership with key opinion leaders in Europe and the US to validate the technology and overall solution's advantages.

- **Core Technology**

The technology is unique in its optimization for the Tibial nerve with regards to anchoring, electrode design, closed loop mechanisms, treatment patient-specific optimization algorithm and more. The optimal form factor was achieved by iterative design and unique production processes. The usability profile has leveraged years of clinical experience and market feedback.

- **Product Profile/Pipeline**

The pipeline includes both a sutured and injectable version of the device. Multiple indications are addressable with the same device and implantation and more indications can be targeted while addressing other target nerves with same technology.

- **What's Next?**

Not to be disclosed